SMARCA4-deficient undifferentiated tumor in the oral cavity: a rare case report and review of the literature.

Oral Surg Oral Med Oral Pathol Oral RadiolApr 27, 2026 (epub)
Case ReportOncology (Medical)Pathology (Anatomic & Clinical)

Kittiphoj Tikkhanarak, Steven Dorris, Jay Saepoo et al.

✦ AI-curated · Sources linked

Case in brief

A 66-year-old man presented with a rapidly enlarging mass in the left posterior maxillary mucosa, accompanied by bone destruction. Histopathological analysis revealed undifferentiated tumor cells with ovoid to epithelioid morphology, and immunohistochemistry showed complete loss of nuclear SMARCA4 expression, confirming a diagnosis of SMARCA4-deficient undifferentiated tumor. The patient died shortly after biopsy, limiting further evaluation.

Diagnostic / clinical pearl

Clinicians should be aware of SMARCA4-deficient undifferentiated tumors in the oral cavity to prevent misclassification and ensure timely management, including evaluation for potential metastatic disease.

Source

PubMed · PMID 42168048

Published in Oral Surg Oral Med Oral Pathol Oral Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.